Nifty 50
- Max Healthcare₹994.7047.60 (5.03%)
- Tata Motors PV₹261.50-25.90 (-9.01%)
- ITC₹294.359.35 (3.28%)
- Tata Steel₹182.78-3.90 (-2.09%)
- Bharti Airtel₹2,157.4051.40 (2.44%)
- JSW Steel₹1,326.10-21.90 (-1.62%)
- HDFC Life Insurance ₹606.6014.35 (2.42%)
- Bajaj Finance₹1,101-16.00 (-1.43%)
- Tata Consumer ₹1,099.9020.90 (1.94%)
- Adani Enterprises₹2,652.50-35.50 (-1.32%)
- Apollo Hospitals₹8,688162.00 (1.90%)
- Hindalco Industries₹933-10.60 (-1.12%)
- Eternal₹369.706.05 (1.66%)
- Coal India₹399.10-4.40 (-1.09%)
- SBI Life Insurance ₹1,81929.10 (1.63%)
- Bajaj Auto₹10,740-110.00 (-1.01%)
- Asian Paints₹2,586.2036.20 (1.42%)
- Bajaj Finserv₹1,849.40-15.60 (-0.84%)
- Nestle₹1,280.7017.50 (1.39%)
- InterGlobe Aviation₹5,543.60-43.70 (-0.78%)
- Offerings
- Tools & Platforms
Tools & Calculators
- Open API
- Calculators
- SIP Calculator
- CAGR Calculator
- Compound Interest Calculator
- FD Calculator
- RD Calculator
- EPF Calculator
- Retirement Calculator
- HDFC SIP Calculator
- Mutual Fund Return Calculator
- Lumpsum Calculator
- Step Up SIP Calculator
- ETF SIP Calculator
- Brokerage Calculator
- Equity Margin Calculator
- SWP Calculator
- EMI Calculator
- MTF Calculator
- Margin Pledge Calculator
- Algo Strategy
- Markets
Stocks
F&O
Mutual Funds
- More
Glenmark Launches Allergic Rhinitis Nasal Spray RYALTRIS in Brazil
Authored By PTI | Last Modified: Sep 11, 2026 12:23 PM IST

Open Free Demat Account
New Delhi: Glenmark Pharmaceuticals on Friday said its wholly-owned subsidiary, Glenmark Specialty S.A., has launched RYALTRIS nasal spray in Brazil.
The launch follows regulatory approval from the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA), granted earlier this year.
RYALTRIS is indicated for treating moderate to severe symptoms associated with allergic rhinitis in people aged 12 years and older.
The product introduces the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) to offer a differentiated dual-action treatment, Glenmark Pharma said in a regulatory filing.
Allergic rhinitis affects an estimated 20-30 per cent of Brazil’s population, equivalent to nearly 40 to 60 million people, highlighting a significant disease burden in the country.
Marco Cerato, Executive Vice President & Global Head — Innovative Business, Glenmark Pharmaceuticals, said, “The launch of RYALTRIS in Brazil marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach.” RYALTRIS is Glenmark’s first globally commercialised branded innovative product. It has already received approval in 57 markets worldwide, including the US, European Union, the UK, Australia, South Korea, Russia, and China.
(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)
Disclaimer
The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.
More GLENMARK News
Open Free Demat Account
₹2,651.90
By signing up I certify terms, conditions & privacy policy
Join Us
Add as preferred source on Google


















